Key Insights on Gross Profit: Pharming Group N.V. vs Arrowhead Pharmaceuticals, Inc.

Biotech Giants' Financial Showdown: Pharming vs Arrowhead

__timestampArrowhead Pharmaceuticals, Inc.Pharming Group N.V.
Wednesday, January 1, 201417500021595165
Thursday, January 1, 20153820006590427
Friday, January 1, 201615833311768542
Sunday, January 1, 20173140770992587038
Monday, January 1, 201816142321129203843
Tuesday, January 1, 2019168795577165412447
Wednesday, January 1, 202087992066203056430
Friday, January 1, 2021138287000169670071
Saturday, January 1, 2022232810000188060000
Sunday, January 1, 2023240735000220104000
Monday, January 1, 20243551000
Loading chart...

Data in motion

A Tale of Two Biotech Giants: Pharming Group N.V. vs Arrowhead Pharmaceuticals, Inc.

In the dynamic world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Pharming Group N.V. and Arrowhead Pharmaceuticals, Inc. have showcased intriguing trends in their gross profits. From 2014 to 2023, Pharming Group N.V. consistently outperformed Arrowhead Pharmaceuticals, with a peak gross profit in 2020, reaching approximately 220 million. In contrast, Arrowhead Pharmaceuticals saw a significant rise in 2022, with a gross profit of around 233 million, marking a 47% increase from the previous year. However, 2024 data for Pharming Group N.V. remains elusive, leaving room for speculation. This financial journey highlights the competitive nature of the biotech industry, where strategic innovations and market dynamics play pivotal roles in shaping a company's financial trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025